Related Experiment Videos
Specific oral contraceptive use and venous thromboembolism resulting in hospital admission
Patricia Heuser1, Katrina Tonga, Raewyn Hopkins
1Medical Research Institute of New Zealand, Wellington, New Zealand.
Objective:
To determine whether there is an increased risk of venous thromboembolism (VTE) with anti-androgen oral contraceptives containing cyproterone acetate and ethinyloestradiol.
Methods:
Comparison of the frequency of specific oral contraceptive use in patients aged 15 to 55 years discharged from hospital with radiologically confirmed deep vein thrombosis (DVT) and/or pulmonary embolism (PE) with the expected frequency of use derived from national prescription data.
Main Outcome Measure:
Ratio of observed frequency of specific oral contraceptive use in patients with VTE versus expected frequency of use.
Results:
The rank order for observed versus expected use was anti-androgen > third-generation, > second-generation, > progestogen-only oral contraceptive agents with ratios of 1.93, 1.36, 0.70, and 0.39, respectively.
Conclusion:
The risk of VTE resulting in hospital admission associated with anti-androgen oral contraceptive use is at least as high as with third generation use.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis I: Introduction
Venous Thrombosis IV: Nursing Management
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies